Director of CMC, Analytics

Sigilon Therapeutics is a biopharmaceutical company creating functional cures for chronic diseases using Shielded Living Therapeutics. The Shielded Living Therapeutics product platform consists of novel engineered human cells that are encased in a proprietary immune-shielding matrix and placed in the body. These Shielded Living Therapeutics then produce therapeutic proteins in a programmable and durable fashion, without generating fibrosis or immune rejection. Our pipeline of products in hemophilia, lysosomal storage diseases, and, in collaboration with Eli Lilly, type 1 diabetes, are rapidly advancing toward the clinic. Sigilon was founded and created by Flagship Pioneering in conjunction with Daniel Anderson, Ph.D., and Robert Langer, Sc.D., of the Massachusetts Institute of Technology. Please forward your application via email to

Sigilon Therapeutics is searching for an energized candidate to execute our analytical CMC strategy. The new Director of CMC Analytics will collaborate with R&D to develop, qualify and tech transfer assays to CMO/CRO partners as our lead programs advance into clinical development in 2019. Overall goals are to manage the life cycle of assay development and specifications during CMC development, including providing technical guidance and documentation for CMO/CRO partners. This position will be responsible for development, qualification and support of non-GMP and GMP in process and release testing for both drug substance and drug product and will work closely with other CMC functional areas, R&D, Quality, and outside contractors.